Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Britain Courts Anthropic Amid US Defense Department Dispute 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Apple Turns 50: From Garage Startup to AI Crossroads 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
BASEL, Switzerland and CAMBRIDGE, Mass., July 05, 2017 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics and Samarth Kulkarni, Ph.D., President and Chief Business Officer of CRISPR Therapeutics, will present at the Piper Jaffray GenomeRx Symposium at the New York Palace Hotel in New York, New York.
Event: Piper Jaffray GenomeRx Symposium
Panel: Gene Editing- Moving from Tools To Therapies
Date: Tuesday, July 11, 2017
Time: 12:05 PM EDT
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Basel, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.
MEDIA CONTACTS: Jennifer Paganelli WCG on behalf of CRISPR +1 347-658-8290 [email protected] INVESTOR CONTACT: Chris Brinzey Westwicke Partners for CRISPR +1 339-970-2843 [email protected]
